Degenerative Diseases

Top Story

Adalimumab, IBI303 biosimilar demonstrate comparable safety, efficacy in AS

September 19, 2019
In the Journals

Newly diagnosed cases of AS at increased risk for IMIDs, lower risk for RA

September 16, 2019
Newly diagnosed patients with ankylosing spondylitis in Taiwan demonstrate increased risks for multiple immune-mediated inflammatory diseases, including acute anterior…
FDA News

FDA grants fast track designation to cell therapy for degenerative disk disease

August 27, 2019
The FDA has given its fast track designation to the investigational cell therapy IDCT for the treatment of degenerative disc disease. IDCT (DiscGenics) is an allogeneic…
In the Journals

More than half of patients in AS remission relapse after ceasing infliximab

April 26, 2019
Approximately 58% of patients in clinical remission after taking infliximab for ankylosing spondylitis relapse within 12 months after discontinuing the treatment…
More Headlines »
From OT Europe
Commentary

Hip-spine syndrome presents challenges for surgeons and patients

Orthopaedics Today Europe, February 2018
Per Kjaersgaard-Andersen, MD
The hip-spine syndrome has been recognized for several years, but recently, more aspects of the condition have been…
More »
Video
Meeting News Coverage

VIDEO: A look at allogeneic mesenchymal stem cells

June 26, 2015
More »
Video
Meeting News

VIDEO: ACDF, cervical disc arthroplasty seen as effective, cost-effective in patients with degenerative discs

March 23, 2018
More »